Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.67 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.56 |
| ▸ | WNT3A | P56704 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795332 | 1.00 | ESR1 (0.67) | ESR1CTNNB1WNT3A | |
| SCHEMBL795330 | 1.00 | ESR1 (0.67) | ESR1CTNNB1WNT3A | |
| SCHEMBL31280034 | 1.00 | ESR1 (0.67) | ESR1CTNNB1WNT3A | |
| SCHEMBL806376 | 0.88 | ESR1 (0.56) | ESR1CTNNB1WNT3A | |
| SCHEMBL16550609 | 0.86 | ESR1 (0.62) | ESR1CTNNB1WNT3A | |
| SCHEMBL16550606 | 0.86 | ESR1 (0.62) | ESR1CTNNB1WNT3A | |
| SCHEMBL16550610 | 0.86 | ESR1 (0.62) | ESR1CTNNB1WNT3A | |
| SCHEMBL19125633 | 0.84 | ESR1 (0.71) | ESR1CTNNB1WNT3A | |
| SCHEMBL795002 | 0.83 | ESR1 (0.70) | ESR1CTNNB1WNT3A | |
| SCHEMBL795001 | 0.83 | ESR1 (0.70) | ESR1CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | claimed |
| EP-2735562-B1 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | claimed |
| EP-2735562-A1 | Estrogen receptor modulators and uses thereof | Seragon Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | claimed |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | claimed |
| EP-2616445-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | claimed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | claimed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11676731-B2 | Diagnostic and therapeutic methods for the treatment of breast cancer | GENENTECH, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220044819-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR THE TREATMENT OF BREAST CANCER | GENENTECH, INC. | 2022-02-10 | — | — | US | disclosed |
| US-11081236-B2 | Diagnostic and therapeutic methods for the treatment of breast cancer | GENENTECH, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3837548-A2 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR THE TREATMENT OF BREAST CANCER | F. Hoffmann-La Roche AG (CH) | 2021-06-23 | — | — | EP | disclosed |
| US-20200082944-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR THE TREATMENT OF BREAST CANCER | GENENTECH, INC. | 2020-03-12 | — | — | US | disclosed |
| US-20160145691-A1 | NOVEL ESTROGEN RECEPTOR MUTATIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-05-26 | — | — | US | disclosed |
| EP-2735562-B1 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2735562-A1 | Estrogen receptor modulators and uses thereof | Seragon Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2616445-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145691-A1 | NOVEL ESTROGEN RECEPTOR MUTATIONS AND USES THEREOF | ESR1, ESR2, ESRRG | ESR1 1/4885CTNNB1 3099/4885WNT3A 3572/4885 |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | ESR1 4/4885CTNNB1 3075/4885WNT3A 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.